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immune mechanisms mediating tubular 
injury. Tubulitis, invasion of the tubular 
epithelium by inﬁltrating T cells and mac-
rophages, is a diagnostic feature of acute 
cellular rejection of renal allografts.10 This 
raises the question of whether tubulitis in 
IgAN progressors recapitulates the same 
process. The answer is negative. As van 
Es et al.5 document, there is a paucity of 
macrophages and CD4+ T lymphocytes 
inﬁltrating tubules of early IgAN progres-
sors. In contrast, the tubulitis pattern of 
renal allografts is full of macrophages and 
mostly of CD4+ and CD8+ T cells that 
contain cytotoxic granules (perforin and 
granzyme A/B) or the cytotoxic eﬀector 
ligand FasL.10 The absence of both per-
forin and granzyme A/B from NKG7+/
CD8+ IELs in IgAN progressors is another 
important feature that contrasts with 
the allograft-inﬁltrating CD8+ cytotoxic 
T lymphocytes. Consequently, what are the 
immune mechanisms engaged by NKG7+/
CD8+ IELs that inﬂict tubular injury? The 
answer is unknown. However, on the basis 
of the localization of NKG7+/CD8+ IELs 
in intact and atrophic tubules, we postu-
late two complementary mechanisms of 
adaptive and innate CD8+ T cell-mediated 
tubular injury. The ﬁrst mechanism (sche-
matized in Figure 1a) proposes that the 
T-cell receptors on NKG7+/CD8+ cells 
mediate the cytotoxic response to either 
cross-presented exogenous antigen or 
an endogenous antigen produced by the 
tubules. Also, the antiapoptotic action 
of transforming growth factor-β and 
interleukin-15, along with the expression of 
CD103 that binds to E-cadherin on tubular 
cells, allows NKG7+/CD8+ IELs to persist 
and cause disruption of the tubular struc-
ture and function. The second mechanism 
(schematized in Figure 1b) proposes the 
innate immune response of the NKG7+/
CD8+ IELs as a mediator of tubulitis. The 
primary function of sentinel CD8+ IELs is 
to sustain epithelial integrity by eliminat-
ing stressed cells. The CD8+ IELs express 
a variety of NK cell–lineage receptors, 
among which is the NKG2D activating 
receptor. Under stress conditions, epithelial 
cells express major histocompatibility com-
plex class I chain-related proteins (MICA 
or MICB) that serve as ligands of NKG2D, 
hence targeting the cells for cytolysis and 
elimination. These are minimal models 
inspired by the study of van Es et al.5 
Their clinical relevance needs to be ascer-
tained in future investigations.
The seminal report by van Es et al.5 
will enhance the clinical utility of renal 
biopsy early in IgAN to predict progres-
sion. Importantly, the novel discovery 
of NKG7+/CD8+ IELs’ association with 
tubulitis implicates this specialized T-cell 
subset as a mediator of nephron injury. 
Finally, we envisage that targeted inhibi-
tion of NKG7+/CD8+ cells could be of 
therapeutic value, especially as an adjunct 
supplement to other therapeutic strategies 
aimed at IgAN.
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The challenge of discovering 
patient-level cardiovascular risk 
factors in chronic kidney disease
R Agarwal1
The goal of developing a CKD-specific cardiovascular risk score remains 
elusive and difficult. One approach to develop such a score is to 
evaluate conventional cardiovascular risk factors in an outcomes model. 
Nontraditional risk factors such as albuminuria can then be tested to 
evaluate the predictive value of these markers over and above traditional 
risk factors for patient-level decision making.
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In 1948, the United States Public Health 
Service initiated a community-based 
epidemiological study in Framingham, 
Massachusetts, to uncover environmental 
and personal factors associated with the 
subsequent appearance and progres-
sion of cardiovascular diseases.1 At ﬁrst 
examination of this cohort, 898 men and 
1,107 women aged 45–62 who appeared 
clinically well underwent a thorough 
history, physical examination, and labo-
ratory evaluation.2 In 1957, a report of 
a 4-year follow-up revealed 52 cases of 
coronary heart disease in men and 32 
cases in women. Blood pressure, relative 
body weight, and the serum cholesterol 
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concentration were found to be elevated 
in those who developed the disease. From 
this experiment, the term ‘risk factor’ 
was born, so named because it helps in 
the assessment of future cardiovascular 
events. Age, sex, smoking, hypertension, 
and serum cholesterol levels remain the 
most enduring risk factors because these 
‘traditional’ risk factors appear to contain 
most of the information deemed neces-
sary to predict cardiovascular events. 
More recently, the presence of additional 
— nontraditional — risk factors has been 
linked to the risk of future cardiovascu-
lar events (Figure 1). Although nontra-
ditional risk factors may increase the 
relative risk of future clinical cardiovas-
cular events, such an increase in relative 
risk may not reach a magnitude that is 
sufficient to improve individual-level 
decision making.3
An evaluation of a recent study from 
the Framingham Oﬀspring Cohort oﬀers 
insights into the relative importance of 
nontraditional risk factors as predictors 
of population risk vis-à-vis prediction 
of patient-level risk.4 Between 1995 and 
1998, Wang et al. examined participants 
in the Framingham Heart Study and fol-
lowed them for up to 10 years for cardio-
vascular events or death. A panel of 
biomarkers of inﬂammation (C-reactive 
protein), endothelial function (homo-
cysteine, urinary albumin-to-creatinine 
ratio), thrombosis–ﬁbrinolysis pathway 
(fibrinogen, D-dimer, plasminogen-
activator inhibitor type 1), and neuro-
hormones (B-type natriuretic peptide, 
N-terminal pro-ANP, serum aldosterone, 
plasma renin) was used to predict risk 
over and above conventional risk fac-
tors (age, sex, body mass index, serum 
creatinine, smoking, blood pressure, 
total cholesterol, high-density lipopro-
tein cholesterol, diabetes mellitus). Only 
two biomarkers — urinary albumin-to-
creatinine ratio and B-type natriuretic 
peptide — emerged as statistically sig-
niﬁcant epidemiological risk factors over 
and above conventional risk factors for 
future cardiovascular events. But for indi-
vidual decision making, the incremental 
value of even these statistically signiﬁcant 
population-level risk factors was small. 
The area under receiver operating char-
acteristic (ROC) curve that took age, sex, 
and conventional risk factors into account 
to predict cardiovascular events was 0.76, 
whereas the comparable area under ROC 
curve that took age, sex, and multi-marker 
strategy into account was 0.70. A combi-
nation of the conventional and newer risk 
factors yielded only a small increment in 
area under ROC curve to 0.77.
In contrast to the two markers that were 
predictive of cardiovascular events, there 
were ﬁve markers that were of statistical 
importance in the Cox model over and 
above conventional risk factors to predict 
death. These were B-type natriuretic pep-
tide, homocysteine, renin, C-reactive pro-
tein, and urinary albumin-to-creatinine 
ratio. The area under ROC curve that took 
age, sex, and conventional risk factors into 
account to predict death was 0.80, whereas 
the comparable area under ROC curve 
that took age, sex, and multi-marker strat-
egy into account was 0.79. A combination 
of the conventional and newer risk fac-
tors yielded only a small increase in area 
under ROC curve to 0.82. Thus, even an 
extensive panel of biomarkers was unable 
to meaningfully alter the predictive utility 
of nontraditional risk factors.
More recently, chronic kidney disease 
(CKD) itself has been recognized to con-
fer increased cardiovascular risk.5 In 
patients with CKD, it is well recognized 
that the Framingham risk score under-
estimates cardiovascular risk, and thus 
an alternative strategy for cardiovascu-
lar risk proﬁling equally as robust as the 
Framingham risk score in patients with 
CKD is not available.
To provide more reliable risk strati-
ﬁcation and explore the provenance of 
heightened risk for cardiovascular events, 
several investigators have explored non-
traditional risk factors.6 The hunt for 
nontraditional risk factors that may be 
etiologically significant is exemplified 
by the humbling story of hyperhomo-
cysteinemia. Although elevated homo-
cysteine concentration is also associated 
with higher blood pressure, diabetes 
mellitus, and CKD, epidemiological 
observations demonstrated that hyper-
homocysteinemia was associated with 
increased atherothrombotic risk after 
multivariate adjustment. Thus drugs that 
lower homocysteine, such as folic acid 
and pyridoxine, seemed attractive choices 
to reduce this cardiovascular risk factor. 
Disappointingly, randomized trials have 
not provided any support for this hypoth-
esis.7 Thus, homocysteine appears to be 
a marker, not a mediator, of increased 
atherothrombotic risk in patients with 
or without CKD.
Another non-conventional risk factor 
of great interest is the presence of inﬂam-
mation, which is frequently activated in 
patients with CKD and may contribute to 
accelerated atherosclerosis.8 Low-grade 
Figure 1 | Impact of traditional and nontraditional risk factors and CKD on cardiovascular 
events. Traditional risk factors are causally linked to cardiovascular events. Chronic kidney disease 
(CKD) also elevates the risk of cardiovascular events. The independent role of nontraditional risk 
factors in patient-level cardiovascular risk is less clear. CKD-specific, cardiovascular risk factors for 
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inflammation can be measured by 
high-sensitivity C-reactive protein (CRP). 
Elevated levels of CRP are associated with 
elevated cardiovascular risk. Weiner et 
al.9 (this issue) explore the impact of 
CKD, inﬂammation, and the interaction 
of CKD and inﬂammation on cardiovas-
cular events in two well-characterized 
cohorts from the Cardiovascular Health 
Study and the Atherosclerosis in Com-
munities Study. The three criteria deﬁning 
inﬂammation were the highest quartile of 
ﬁbrinogen, the lowest quartile of albumin, 
and the highest quartile of race-speciﬁc 
white blood cell count; the diagnosis of 
inﬂammation required that two of the 
three criteria be present. Inﬂammation 
was associated with increased hazards 
for stroke, cardiac events, or death after 
adjustment for conventional risk factors 
that ranged between 35% and 50%. In 
patients with CKD, the hazard ratio was 
similarly elevated between 15% and 25%. 
These data conﬁrm previous results from 
the Cardiovascular Health Study cohort 
of an association of cardiovascular mor-
tality with markers of inﬂammation such 
as CRP and interleukin-6.10 When com-
pared with a reference group of patients 
without inﬂammation and without CKD, 
those with CKD alone had an increase in 
hazards of hard cardiovascular end points 
of 20%–60%, those with inﬂammation 
alone had an increase of 40%–60%, and 
those with both inﬂammation and CKD 
had an increase in hazards of 40%–100%. 
The interaction of inflammation and 
CKD was not statistically significant. 
Thus, the central message of this report 
is that inﬂammation is associated with 
increased cardiovascular risk in those 
with CKD that is similar to the risk in 
those without CKD; there is no special 
predilection for cardiovascular events in 
inﬂamed patients with CKD. As an aside, 
the investigators demonstrated that the 
combination of high white blood cell 
count and low serum albumin concen-
tration was similar to elevated CRP in 
predicting outcomes.
Although the authors do not report the 
predictive performance for cardiovascu-
lar events of these inﬂammation biomar-
kers as area under ROC curves, given 
the low hazard ratios it is very unlikely 
that incorporation of these inﬂamma-
tion biomarkers in the Framingham 
risk score will improve our ability to 
predict cardiovascular events or death 
in patients with CKD. In fact, the area 
under ROC curves was not improved in 
the Cardiovascular Health Study when 
markers of inﬂammation were added to 
traditional risk factors.10 Similar results 
have emerged from general-population 
surveys. For example, the Dallas Heart 
Study investigators measured CRP in 
3,373 randomly selected, community-
dwelling subjects and performed elec-
tron-beam computed tomography scans 
to detect coronary calcification and 
magnetic resonance imaging to meas-
ure aortic plaque.11 They found a mod-
est association of inﬂammation with the 
prevalence of subclinical atherosclerosis. 
But this association was not independ-
ent of traditional cardiovascular risk fac-
tors. Taken together, these results do not 
support the routine use of CRP in the 
general population or in patients with 
CKD for patient-level cardiovascular 
risk assessment.
The goal of developing a CKD-speciﬁc 
cardiovascular risk score remains elusive 
and diﬃcult. An approach provided by 
Framingham Heart Study investigators 
where cardiovascular risk is systemati-
cally evaluated for each risk factor over 
and above the traditional risk may be a 
valuable lesson for future research to 
define cardiovascular risk in patients 
with CKD for patient-level decision 
making.4 Nontraditional risk factors 
such as albuminuria, cystatin C, B-type 
natriuretic peptide, and CRP can then be 
tested to evaluate the predictive value of 
these markers over and above traditional 
risk factors. Subsequently, measures 
to lower the level of these risk factors 
with dietary, lifestyle, or pharmacologi-
cal maneuvers can be tested to ascertain 
whether any of these risk factors are caus-
ally associated with cardiovascular risk. 
Perhaps this strategy can help unravel the 
mystery of elevated cardiovascular risk in 
CKD patients and assist decision making 
at the level of the individual patient.
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